LINCOLN PHARMA LTD (LINCOLN)

Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2026.

Annual Secretarial Compliance Report for the financial year ended March 31, 2026.

Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof.

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Lincoln Pharmaceuticals Ltd 2 CIN NO. L24230GJ1995PLC024288 3 Report filed for FY 2025-2026 Details of the Current block (all figures in Rs crore): 4 2 – year block period (Specify financial years)* 2025-26 , 2026-27 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T – 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T – 1) which was carried forward to FY(T)}(f) = (b) – [(c) – (e)]{ If the calculated value is zero or negative, write “nil”}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 – year Block period (Specify financial years)2025-26 , 2026-27 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) – (e)}#0.00 Name of the Company Secretary :-Trusha ShahDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Darshit Shah Designation : -Chief Financial Officer Date: 05/05/2026

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyLincoln Pharmaceuticals Ltd 2CIN NO.L24230GJ1995PLC024288 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: TRUSHA SHAH Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: TRUSHASHAH@LINCOLNPHARMA.COM Name of the Chief Financial Officer: DARSHIT SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: DARSHIT@LINCOLNPHARMA.COM Date: 16/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.